Search
Anatibant
go.drugbank.com/drugs/DB05038ExperimentalAnatibant is a selective, very potent, small-molecule Bradykinin B2 receptor antagonist. It is developed for the for the treatment of traumatic brain injury (TBI).
AZD-2836
go.drugbank.com/drugs/DB06031InvestigationalAZD-2836 is an inhibitor of the nonstructural protein 5A (NS5A).[A264853] The drug is being investigated for treatment of hepatitis C because AZD-2836 has in vitro anti-HCV activity.[A264858]
LGD-1550
go.drugbank.com/drugs/DB05785ExperimentalLGD-1550 is an orally-active synthetic aromatic retinoic acid agent with potential antineoplastic and chemopreventive activities.
Hexobarbital
go.drugbank.com/drugs/DB01355ExperimentalA barbiturate that is effective as a hypnotic and sedative.
Flunoxaprofen
go.drugbank.com/drugs/DB13317ExperimentalCategories: Genito Urinary System and Sex HormonesTiclopidine
go.drugbank.com/drugs/DB00208ApprovedIt is a prodrug that is metabolised to an active form, which blocks the ADP receptor that is involved in GPIIb/IIIa receptor activation leading to platelet aggregation. … Ticlopidine is an effective inhibitor of platelet aggregation.
Muraglitazar
go.drugbank.com/drugs/DB06510InvestigationalMuraglitazar (Bristol-Myers Squibb/Merck) is a new agent under investigation for the treatment of patients with type 2 diabetes. … In addition to improvements in blood glucose and hemoglobin A1c (HbA1c), muraglitazar treatment is associated with a substantial reduction in triglycerides (TGs), an increase in HDL-C, and a modest decrease
XP21279
go.drugbank.com/drugs/DB06319InvestigationalXP21279 is a prodrug of [Levodopa], a dopamine precursor used in the management of Parkinson's disease.
Pascolizumab
go.drugbank.com/drugs/DB06560InvestigationalPascolizumab (SB 240683) is a humanized anti-interleukin-4 antibody with therapeutic potential in asthma.